Conatus: Major Contender For The NASH Market

Fast ENCORE-NF recruitment is a huge plus for moving emricasan one step closer to FDA approval.<p>The market opportunity for NASH is expected to grow …


Express Scripts to limit opioids; doctors concerned | Miami Herald

The nation's largest pharmacy benefit manager will soon limit the number and strength of opioid drugs prescribed to first-time users.<p>The move by …


Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects

Is it telling of some frothiness in the market that the industry's most valuable late-stage asset is thought to be Biogen's (NASDAQ:BIIB) Alzheimer's …


India introduces price controls for knee implants

NEW DELHI (Reuters) - India has capped prices of orthopaedic knee implants, in the country's latest move to bring down prices of medical devices.<p>The introduction of price controls marks the latest step by Prime Minister Narendra Modi's government to make drugs and medical devices more affordable. …


Perspectives: Drug Companies Getting Stingy With Subsidies; Supreme Court Deals Blow To Consumers

Read recent commentaries about drug-cost issues.

Health Policy

Biocon withdraws application for breast cancer biosimilars, shares fall

Shares of Biocon took a hammering on Wednesday after it withdrew its application for Trastuzumab and Pegfilgrastim, biosimilars for breast cancer


Ascendis Pharma A/S (ASND) Presents At Wedbush PacGrow Healthcare Conference - Slideshow

The following slide deck was published by Ascendis Pharma in conjunction with this event.<p>116<p>Click to enlarge


Drugmakers ‘Game The System And Game The Rules,’ FDA Head Gottlieb Says

News outlets report on stories related to pharmaceutical pricing.

Health Care

Novartis: Why Entresto Is Key

Entresto is finally taking away solid market share away from generics.<p>If Novartis succeeds in having a branded drug overtake generics, it may …


Warning issued over illegal medicines after woman fined for selling pills from Northern Ireland food shop

A woman has been convicted of the sale and supply of illegal prescription medicines from her Eastern European convenience food store in …

UK News

Aurinia: Strong Potential With Focus On Lupus Related Kidney Ailment

Aurinia reported start of Phase 3 trials for lead drug candidate voclosporin.<p>The drug, being developed for addressing Lupus Nephritis, showed strong …


Why Gilead Sciences Might Not Make an Oncology Acquisition -- The Motley Fool

Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.<p>Is <b>Gilead</b> …


Martin Shkreli behind bars?

"I don't think I'm going to jail," convicted fraudster Martin Shkreli told Fox News, suggesting that "just being a flamboyant and personable figure" …


What’s Harder Than Making Copycat Biotech Drugs? Selling Them

Big-name drugmakers want to profit from selling lower-priced copies of rivals’ expensive biotechnology drugs. Patients and doctors want to pay less …

Johnson & Johnson

Merck CEO 'pathetic' to make political statement by exiting manufacturing council: Shkreli

Former Turing Pharmaceuticals CEO Martin Shkreli on Tuesday called out Merck CEO Kenneth Frazier for leaving President Donald Trump’s American Manufacturing Council.<p>In his first television interview since being convicted of two counts of securities fraud and one count of conspiracy, Shkreli said …

Martin Shkreli

From the son of a janitor to CEO of Merck: Meet Kenneth Frazier, who's getting praised after leaving Trump's manufacturing council

• <b>Merck CEO Kenneth Frazier left the president's manufacturing council on Monday.</b>• <b><br>The move attracted some negative attention from President Donald Trump, but many in the healthcare industry came to Frazier's defence.</b>• <b><br>Frazier is the CEO of one of the biggest pharmaceutical companies in the world.</b><p>Merck …


Insulin Maker Learns Brutal Lesson: Sometimes Innovation Doesn't Pay

Danish drug giant Novo Nordisk AS is living through a corporate nightmare that any CEO might recognize from business school.<p>After the company concentrated on making essentially one product better and better—and charging more and more—customers have suddenly stopped paying for all that improvement. …


Martin Shkreli: I was targeted for being 'flamboyant and personable'

Martin Shkreli, the drug CEO who was just found guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud, said …

Martin Shkreli

South Carolina Becomes The Latest State To Sue Purdue Phrama Over Deceptive Opioid Marketing Practices

Purdue Pharma has paid out over half a billion dollars in the past decade in various lawsuits that have accused it of contributing to the opioid epidemic by aggressively marketing Oxycontin, and it just might have to pony up another settlement, at least if South Carolina has its way. The state is …

Opioid Epidemic

Facing deadlines, drug makers move to beef up defenses against counterfeit medications

Most people trust that their medicine matches the description on the bottle. But what if it doesn’t?<p>Counterfeit drugs look a lot like the real deal, …

Flimsy evidence behind many FDA approvals

(Reuters Health) - Many drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) lack clear evidence of safety and effectiveness, and the same is true for most high-risk medical devices, according to two new reports in the Journal of the American Medical Association.<p>The …


The New Innovator’s Dilemma: When Customers Won’t Pay for Better

For almost a century, pharmaceutical giant Novo Nordisk rolled out new products at higher prices. That strategy has come to a screeching halt<p>Danish drug giant Novo Nordisk AS is living through a corporate nightmare that any CEO might recognize from business school.<p>After the company concentrated on …

Fast-tracking drug development one robot at a time

The pharmaceutical industry is going through a tough phase as it strives to manage high R&D costs and skyrocketing drug prices, along with the spike …

Medical Technology

South Carolina Joins States Suing Purdue Pharma Over Opioids

South Carolina joined a growing list of states suing opioid makers, a signal of increasing pressure on pharmaceutical companies as the addiction …


South Carolina Sues Purdue Pharma, Alleging Deceptive Opioid Marketing

The suit follows one filed against drug distributors by Birmingham, Ala., for allegedly ‘dumping’ painkillers into the city<p>Lawsuits filed over the opioid crisis continued to mount this week, with an action Tuesday brought by South Carolina against drugmaker Purdue Pharma LP and an earlier suit by …

South Carolina

Martin Shkreli trial: A timeline of events

Martin Shkreli, the embattled pharmaceutical CEO, was convicted earlier this month on charges that he deceived investors through failed hedge funds – but he doesn’t think he’ll be going to jail.<p>The so-called “Pharma Bro” was charged with securities fraud, conspiracy to committee securities fraud …


Medicare Part D

In its first decade, Medicare Part D has been popular with beneficiaries, providing important benefits to more than forty million people at lower …


Which M&A made our best-and-worst ballot? Vote for the deals of the decade

The word “deal” has a curiously apt set of meanings when it comes to M&A. It’s the hook-up of two companies, of course. But according to the Oxford …


CIO 100 2017 Winners Database

How to Use This Chart:Learn about the 2017 CIO 100 Award winners and their winning projects with this interactive chart. Click on the company name to …

Customer Service

Novo Nordisk A/S Continues Its Comeback -- The Motley Fool

A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.<p><b>Novo Nordisk</b> (NYSE:NVO) released earnings for …